计算溶液所需的质量、体积或浓度。
This is a demo store. No orders will be fulfilled.
| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| G649951-5mg |
5mg |
期货 ![]() |
| |
| G649951-10mg |
10mg |
期货 ![]() |
| |
| G649951-50mg |
50mg |
期货 ![]() |
| |
| G649951-100mg |
100mg |
期货 ![]() |
|
| 别名 | GSK-3β 抑制剂 2 |
|---|---|
| 规格或纯度 | ≥96% |
| 英文名称 | GSK-3β inhibitor 2 |
| 生化机理 | GSK-3β 抑制剂 2(化合物 3)是一种强效、选择性和口服活性 GSK-3β 抑制剂,其 IC 50 为 1.1 nM。GSK-3β 抑制剂 2 可以穿过血脑屏障。GSK-3β 抑制剂 2 具有治疗阿尔茨海默病的潜力。 |
| 储存温度 | -20°C储存 |
| 运输条件 | 超低温冰袋运输 |
| 作用类型 | 抑制剂 |
| 产品介绍 |
GSK-3β inhibitor 2 (Compound 3) is a potent, selective and orally active GSK-3β inhibitor with an IC 50 of 1.1 nM. GSK-3β inhibitor 2 can cross the blood-brain barrier. GSK-3β inhibitor 2 has the potential for Alzheimer's disease In Vitro The pyridine carboxamide of GSK-3β inhibitor 2 (Compound 3) makes hydrogen bonds with the hinge V135 backbone amide, and the carbonyl oxygen of the thiazolyl primary amide formed a critical hydrogen bond with K85. The quality of the electron density for the methyl group of the methoxy moiety in GSK-3β inhibitor 2 does not allow its unambiguous placement in the model, but a small molecule crystal structure of GSK-3β inhibitor 2 determined by single crystal X-ray diffraction method confirmed the intramolecular hydrogen bonding between the methoxy -O- and the amide N-H in GSK-3β inhibitor 2. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo The elevation of hyperphosphorylated Tau (pTau) is mimicked in LaFerla 3xTg-C57BL6 mice, and accordingly, these mice are used as an in vivo model of Alzheimer’s disease. GSK-3β inhibitor 2 (Compound 3) shows a significant reduction in pTau396 when administered orally at 30 mg/kg as a nanosuspension to LaFerla 3xTg-C57BL6 male mice. GSK-3β inhibitor 2 shows only modest brain exposure (B/P = 0.26) as determined as a single time point . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Form:Solid IC50& Target:GSK-3β 1.1 nM (IC 50 ) |
| 纯度 | ≥96% |
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
| 分子类型 | 小分子 |
|---|---|
| IIUPAC Name | 2-[2-(cyclopropanecarbonylamino)pyridin-4-yl]-4-methoxy-1,3-thiazole-5-carboxamide |
| INCHI | 1S/C14H14N4O3S/c1-21-13-10(11(15)19)22-14(18-13)8-4-5-16-9(6-8)17-12(20)7-2-3-7/h4-7H,2-3H2,1H3,(H2,15,19)(H,16,17,20) |
| InChi Key | CYADPSMQNARVII-UHFFFAOYSA-N |
| Smiles | COC1=C(SC(=N1)C2=CC(=NC=C2)NC(=O)C3CC3)C(=O)N |
| Isomeric SMILES | COC1=C(SC(=N1)C2=CC(=NC=C2)NC(=O)C3CC3)C(=O)N |
| PubChem CID | 73333976 |
| 分子量 | 318.35 |
| 溶解性 | DMSO : 5 mg/mL (15.71 mM; Need ultrasonic) |
|---|---|
| 分子量 | 318.350 g/mol |
| XLogP3 | 1.000 |
| 氢键供体数Hydrogen Bond Donor Count | 2 |
| 氢键受体数Hydrogen Bond Acceptor Count | 6 |
| 可旋转键计数Rotatable Bond Count | 5 |
| 精确质量Exact Mass | 318.079 Da |
| 单同位素质量Monoisotopic Mass | 318.079 Da |
| 拓扑极表面积Topological Polar Surface Area | 135.000 Ų |
| 重原子数Heavy Atom Count | 22 |
| 形式电荷Formal Charge | 0 |
| 复杂度Complexity | 446.000 |
| 同位素原子数Isotope Atom Count | 0 |
| 定义的原子立体中心计数Defined Atom Stereocenter Count | 0 |
| 未定义的原子立体中心计数Undefined Atom Stereocenter Count | 0 |
| 定义的键立体中心计数Defined Bond Stereocenter Count | 0 |
| 未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
| 所有立体化学键的总数The total count of all stereochemical bonds | 0 |
| 共价键合单元计数Covalently-Bonded Unit Count | 1 |